Posted by Michael Wonder on 09 Apr 2024
Syros receives fast track designation from the FDA for tamibarotene for the treatment of newly diagnosed unfit AML with RARA gene over-expression
9 April 2024 - Syros Pharmaceuticals today announced that the US FDA has granted fast track designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukaemia with RARA over-expression as detected by an FDA approved test in adults who are over age 75 years or who have co-morbidities that preclude the use of intensive induction chemotherapy.
Tamibarotene, an oral first in class selective retinoic acid receptor alfa agonist, is currently being evaluated in combination with venetoclax and azacitidine for the treatment of newly diagnosed acute myeloid leukaemia patients with RARA gene over-expression.
